FIGURE 7.

BETi effects on reactive oxygen species (ROS) production in stimulated neutrophils from enzyme replacement therapy–treated Fabry disease patients. (A) percent change in ROS driven by apabetalone. Data were normalized to the stimulation condition (LPS + DMSO) in individual patients (n = 7). (B) ROS level fold change to baseline (DMSO) in LPS or IFN‐γ stimulated neutrophils with apabetalone co‐treatment (n = 3). (C) Apabetalone treatment (4 h) downregulates LPS induced NOX2 gene expression in a dose‐dependent manner. Data were normalized to the LPS + DMSO condition in individual patients. In (A) and (C), Data were normalized to the LPS + DMSO condition in individual patients. Bar graphs show the mean ± SEM. Statistical significance was determined by Mann–Whitney test or one‐way ANOVA followed by Dunnett's multiple comparison test relative to stimulated conditions (LPS + DMSO or IFN‐γ + DMSO). *p < .05, **p < .01, ***p < .001, ****p < .0001